Overview

Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

Status:
Completed
Trial end date:
2017-10-04
Target enrollment:
Participant gender:
Summary
To demonstrate the contraceptive efficacy of LF111 . To demonstrate the safety and tolerability of LF111 and assessment of pharmacokinetics of LF111.
Phase:
Phase 3
Details
Lead Sponsor:
Laboratories Leon Farma, S.A.
Collaborator:
Chemo France
Treatments:
Contraceptive Agents
Contraceptives, Oral
Contraceptives, Oral, Hormonal
Drospirenone